Role of diffusion-weighted magnetic resonance imaging in the differential diagnosis of focal hepatic lesions

Naoto Koike, Akihiro Cho, Katsuhiro Nasu, Kazuhiro Seto, Shigeyuki Nagaya, Yuji Ohshima, Nobuhiro Ohkohchi

Naoto Koike, Yuji Ohshima, Department of Surgery, Seirei Sakura Citizen Hospital, 2-36-2 Ebaradai, Sakura, Chiba 285-8765, Japan
Akihiro Cho, Department of Surgery, Chiba Cancer Center, 666-2 Nitona, Chuhoku, Chiba 260-8717, Japan
Katsuhiro Nasu, Department of Radiology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan
Kazuhiro Seto, Department of Radiology, Seirei Sakura Citizen Hospital, 2-36-2 Ebaradai, Sakura, Chiba 285-8765, Japan
Shigeyuki Nagaya, Department of Radiology, Seirei Mikatabara Hospital, 3453 Mikatabara, Kitaku, Hamamatsu, Shizuoka 433-8558, Japan
Nobuhiro Ohkohchi, Department of Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan

Author contributions: Koike N wrote the paper; Cho A designed research; Koike N, Seto K, Nagaya S and Ohshima Y contributed to the imaging processing and analysis; Nasu K and Ohkohchi N critically revised the paper with an important conceptual and editorial input.

Correspondence to: Dr. Naoto Koike, Department of Surgery, Seirei Sakura Citizen Hospital, 2-36-2 Ebaradai, Sakura, Chiba 285-8765, Japan. naotk@sis.seirei.or.jp
Telephone: +81-43-4861151 Fax: +81-43-4868696
Received: August 15, 2009 Revised: October 26, 2009 Accepted: November 2, 2009 Published online: December 14, 2009

Abstract

AIM: To evaluate the utility of diffusion-weighted imaging (DWI) in screening and differential diagnosis of benign and malignant focal hepatic lesions.

METHODS: Magnetic resonance imaging (MRI) examinations were performed using the Signa Excite XI Twin Speed 1.5T system (GE Healthcare, Milwaukee, WI, USA). Seventy patients who had undergone MRI of the liver [29 hepatocellular carcinomas (HCC), four cholangiocarcinomas, 34 metastatic liver cancers, 10 hemangiomas, and eight cysts] between April 2004 and August 2008 were retrospectively evaluated. Visualization of lesions, relative contrast ratio (RCR), and apparent diffusion coefficient (ADC) were compared between benign and malignant lesions on DWI. Superparamagnetic iron oxide (SPIO) was administered to 59 patients, and RCR was compared pre- and post-administration.

RESULTS: DWI showed higher contrast between malignant lesions (especially in multiple small metastatic cancers) and surrounding liver parenchyma than did contrast-enhanced computed tomography. ADCs (mean ± SD × 10⁻³ mm²/s) were significantly lower (P < 0.05) in malignant lesions (HCC: 1.31 ± 0.28 and liver metastasis: 1.11 ± 0.22) and were significantly higher in benign lesions (hemangiomia: 1.94 ± 0.37 and cyst: 2.61 ± 0.45) than in the surrounding hepatic tissues. RCR between malignant lesions and surrounding hepatic tissues significantly improved after SPIO administration, but RCRs in benign lesions were not improved.

CONCLUSION: DWI is a simple and sensitive method for screening focal hepatic lesions and is useful for differential diagnosis.

© 2009 The WJG Press and Baishideng. All rights reserved.

Key words: Hepatic tumor; Liver imaging; Magnetic resonance imaging; Diffusion-weighted imaging; Apparent diffusion coefficient

Peer reviewer: Dr. Serdar Karakose, Professor, Department of Radiology, Meram Medical Faculty, Selcuk University, Konya 42080, Turkey

Koike N, Cho A, Nasu K, Seto K, Nagaya S, Ohshima Y, Ohkohchi N. Role of diffusion-weighted magnetic resonance imaging in the differential diagnosis of focal hepatic lesions. World J Gastroenterol 2009; 15(46): 5805-5812 Available from: URL: http://www.wjgnet.com/1007-9327/15/5805.asp DOI: http://dx.doi.org/10.3748/wjg.v15.i5.5805

INTRODUCTION

Diffusion is the thermally induced motion of water molecules, which is also referred to as Brownian motion. Diffusion-weighted imaging (DWI) is a new magnetic resonance imaging (MRI) technique that provides imaging of diffusion in biological tissues.

DWI has been reported to be useful in evaluating the early stages of brain ischemia. Recent technical developments have reduced the image distortion associated with this technique and have increased the signal-to-noise ratio, thus making DWI of the body feasible. Screening, accurate detection, and characterization of focal hepatic lesions are important for planning...
treatment of malignant hepatic lesions. The differential diagnosis of malignant and benign focal hepatic lesions remains a diagnostic challenge; however, to improve the diagnosis of such lesions, new methods for existing modalities, such as MRI, computed tomography (CT), angiography, and ultrasonography are being developed.

Recently, some studies have reported that the apparent diffusion coefficient (ADC), which is one of calculated parameters of DWI, might be useful for differential diagnosis of benign and malignant lesions in the liver. Recently, some studies have reported that the apparent diffusion coefficient (ADC), which is one of calculated parameters of DWI, might be useful for differential diagnosis of benign and malignant lesions in the liver. Superparamagnetic iron oxide (SPIO)-enhanced MRI was reported to be as useful as CT during arteriportography and CT during hepatic arteriography for diagnosing metastatic liver tumors. SPIO improves the contrast-to-noise ratio (CNR) between focal hepatic lesion and the surrounding liver parenchyma on T2-weighted imaging. SPIO has also been reported to further improve the performance of DWI of the liver because SPIO reduces the signal in normal liver parenchyma.

The purpose of the present study was to retrospectively evaluate the utility of DWI in screening, accurate detection, and differential diagnosis of benign and malignant focal hepatic lesions.

MATERIALS AND METHODS

Patients

We retrospectively evaluated 70 patients (52 men and 18 women; age, 39-86 years; mean age, 65.3 years) with 85 lesions [29 hepatocellular carcinomas (HCC), four cholangiocarcinomas, 34 metastatic liver cancers, 10 hemangiomas, and eight cysts] who had been examined between April 2004 and August 2008. The locations of each focal hepatic lesion were: posterior segment in 32, anterior segment in 33, median segment in 15, and lateral segment in five patients. These lesions measured 1.0 to 10.0 cm (mean 3.1 cm) along their long axes on CT images.

The criteria for selecting patients to evaluate in the present study were as follows: (1) the diagnoses of HCC were pathology confirmed in 25 lesions and other lesions were confirmed by measurement of the serum α-fetoprotein (AFP) level, clinical data, ultrasonography, angiography and CT or MRI or both; (2) hepatic metastasis of primary lesions was pathologically confirmed; (3) the diagnosis of cholangiocarcinomas was pathologically confirmed in three lesions and the other lesion was confirmed by clinical data, ultrasonography, CT and MRI; (4) the diagnosis of cavernous hemangioma and hepatic cysts was confirmed by clinical data, ultrasonography, CT or MRI or both, and follow-up observation.

Imaging protocol

MR examinations were performed using the Signa Excite XI Twin Speed 1.5T system (GE Healthcare, Milwaukee, WI, USA) with a four-channel torso-array coil. Diffusion weighted single-shot echo-planar imaging was performed in individual patients using the following parameters: repetition time/echo time (TR/TE) = 6000/73.1 ms, 7-8 mm thickness, water selective excitation for fat suppression, matrix size = 128 × 128, field of view = 36 cm × 36 cm, number of excitations = 6.0, slice thickness/gap = 8 mm/0 mm, 20 axial slices, scan time = 2 min 24 s, b value = 0 and 1000 s/mm², under free breathing. A parallel imaging technique, array spatial sensitivity encoding technique (ASSET) was used. Motion-probing gradient pulses were placed along three orthogonal oblique directions. Additional post-contrast-enhanced DW images were obtained after intravenous administration of SPIO (Resovist; Bayer Schering Pharma AG, Berlin, Germany). The dose of SPIO was 0.016 mL/kg, corresponding to 0.45 mg/kg of Fe.

Contrast enhanced CT was conducted using the LightSpeed ultra 16-MDCT scanner (GE Healthcare, Milwaukee, WI, USA) with pre- and postcontrast triple-phase (arterial, portal venous, and equilibrium phase) scans after injection of 80 to 100 mL of Iopamidol (Iopamiro; Bayer Schering Pharma AG, Berlin, Germany) at an injection rate of 1.5 to 3.0 mL/s.

Visualization of lesions, relative contrast ratio between the lesion and surrounding liver parenchyma (RCR), and ADC values were compared between benign and malignant lesions on DWI. Analysis and measurements of DWI data was performed using the GE FUNDTCOOL software. All regions of interest (ROI) were created as large as possible in each lesion. In cases with multiple lesions, only the most conspicuous lesion was selected for quantitative measurements. If different types of lesions were mixed (for example, hepatocellular carcinomas and cysts), each lesion was measured.

Visualization of lesions

All but two lesions (CT examinations were not performed in one case of metastatic liver cancer and hemangioma) were evaluated. Two diagnostic doctors performed a visual evaluation of each selected CT image (best phase for CT examinations in individual lesions) and DWI (only before SPIO administration) based on mutual agreement. They classified the visualization of lesions on CT and DWI into three categories according to the following criteria. Grade 1: no or slight visualization and unclear margin. Grade 2: moderate visualization and clear margin. Grade 3: marked visualization and very clear margin.

RCR measurements

SPIO was administered to 59 patients (18 HCC, 26 metastatic liver cancers, 10 hemangiomas, seven cysts) and the RCR was compared before and after SPIO administration to differentiate between benign and malignant lesions. The RCR was calculated by the following equation: \( \text{RCR} = \frac{S_{\text{lesion}}}{S_{\text{liver}}} \), where \( S \) is signal intensity of the lesion and \( S_{\text{liver}} \) was evaluated from hepatic tissue surrounding the lesion. In this paper, the conventional contrast-to-noise ratio analysis was not employed because the standard deviation of the
background could not be measured easily in the images obtained using ASSET.

ADC measurements
ADCs of both focal hepatic lesions and surrounding liver parenchymas (26 HCC, 32 metastatic liver cancers, four cholangiocarcinomas, 10 hemangiomas, eight cysts) were measured in 65 patients. Lesions in the lateral segments were excluded for ADC measurement because their ADC could not be correctly measured in the DWI sequences without simultaneous cardiac gating.

Statistical analysis
ADC and SI were measured twice and averaged. All data are expressed as mean ± SD. The visualization data was statistically analyzed by Wilcoxon’s signed rank test, and RCR and ADC were analyzed by Student’s t test using Prism 4.0 software (GraphPad Software, Inc., San Diego, CA, USA). A P value of < 0.05 was considered statistically significant.

RESULTS
Visualization of lesions
Most malignant lesions were significantly more clearly visualized on DWI than on CT (Table 1). In particular, multiple small focal hepatic lesions were visualized clearly on DWI. Two malignant lesions were not detected on DWI, even though they could be easily detected on enhanced CT. These lesions were HCC just under the diaphragm of the lateral segment with liver cirrhosis. Benign lesions, by contrast, were significantly more poorly visualized on DWI than on CT. Similar to the results of several articles published previously, cysts showed low or no signal intensities in six of eight cases on DWI (in these cases, no signal intensity means lower signal intensities than background signal intensities). DWI visualized most hemangiomas; however, CT was better than DWI for the visualization of hemangiomas.

RCR measurements
The average RCR on DWI before and after SPIO administration is shown in Figure 2. RCR seemed to be significantly improved after SPIO administration in malignant lesions that were metastatic liver cancers (before: 2.39 ± 1.28, after: 4.23 ± 1.34, n = 26) and HCC (before: 1.85 ± 0.58, after: 2.59 ± 1.28, n = 18). On the other hand, the RCR was not significantly improved in benign lesions after SPIO administration. The RCR of cysts was 0.86 ± 0.30 (n = 7) before SPIO administration, because the SI of cysts was lower than background SI on DWI. Therefore, the RCR of cysts increased after SPIO.

Table 1 Visual evaluation of focal hepatic lesions

| Lesions        | Modalities | Grade 1 | Grade 2 | Grade 3 |
|----------------|------------|---------|---------|---------|
| Meta* (n = 33) | CT         | 9       | 17      | 7       |
|                | DWI        |         |         |         |
| HCC* (n = 29)  | CT         | 4       | 19      | 6       |
|                | DWI        | 6       | 11      | 12      |
| Cholangiocarcinoma (n = 4) | CT | 1 | 1 | 2 |
|                | DWI        | 0       | 0       | 4       |
| Cyst* (n = 8)  | CT         | 0       | 1       | 7       |
|                | DWI        | 8       | 0       | 0       |
| Hemangioma* (n = 9) | CT | 0 | 8 | 1 |
|                | DWI        | 5       | 2       | 2       |

Meta: Metastatic liver cancer; HCC: Hepatocellular carcinoma; DWI: Diffusion-weighted imaging; CT: Computed tomography. *P < 0.05.
administration (1.48 ± 0.65) as a result of a decrease in the SI of the liver. The RCR of hemangiomas was 1.58 ± 0.38 (n = 10) before and 2.15 ± 1.10 after SPIO administration. This was not statistically significant. The RCRs of hemangiomas were reduced in three lesions after SPIO administration. One example is shown in Figure 3.

Figure 4 is a case in which multiple small cysts and metastatic tumors of colon cancer were colocalized in the liver. Both cysts and cancers expressed high signal intensities in T2-weighted MR imaging. In contrast, only the metastatic nodules were expressed on DWI after SPIO administration.

ADC measurements

Generally speaking, the lesions showing high signal intensity on DWI demonstrate low ADCs. The average ADCs in our study are shown in Figure 5. The ADCs (mean ± SD × 10^-3 mm^2/s) of malignant lesions, both HCC (1.31 ± 0.28, n = 26) and metastatic liver cancer (1.11 ± 0.22, n = 32), were significantly lower than the ADCs of the surrounding hepatic tissues. The ADC of cholangiocarcinomas was 1.33 ± 0.23 (n = 4). Although this was lower than the ADC of the surrounding hepatic tissue, the difference was not significant.

In benign lesions, the ADCs of both cysts (2.61 ± 0.45, n = 8) and hemangiomas (1.84 ± 0.37, n = 10) were significantly higher than the ADC of the surrounding hepatic tissue. A representative hemangioma is shown in Figure 3, which expressed high signal intensity and high RCR on DWI. A representative hepatic cyst case is shown in Figure 6. The cyst expressed nearly no signal intensity on DWI after SPIO administration. However, the cyst revealed a higher ADC value than the surrounding hepatic tissue on the ADC map.

DISCUSSION

Surgeons need new imaging modalities that can precisely and concisely evaluate malignant lesions. DWI has recently emerged as a tool for detecting cancers in the abdominal organ field[9,13,14]. Positron emission imaging is currently used as a powerful screening tool for malignancy[15]. Some
articles have reported that SPIO-enhanced T2-weighted MR imaging and CT during arteriopography have the best ability to diagnose metastatic liver cancer. However, even with use of these modalities, differentiating...
between malignant tumors and intrahepatic vascular structures (e.g. arterioporal shunts and thin vessels) or benign lesions (e.g. small cysts and hemangiomas) is sometimes difficult. One of the purposes of the current study was to evaluate the potential of DWI for differentiating malignant from benign lesions.

Nasu et al\textsuperscript{[17]} reported the sensitivity of DWI for detecting small metastases to be higher than that of SPIO-enhanced T2-weighted MR imaging because metastatic tumors tended to appear larger on DWI than on T2-weighted images, and intrahepatic vascular signals were suppressed on DWI. Parikh et al\textsuperscript{[18]} also reported that DWI was better than standard breath-hold T2-weighted imaging for the detection of focal hepatic lesions. In particular, they found much higher contrast between HCC and cirrhotic liver on DWI than on T2-weighted images. The contrasts between HCC and cirrhotic liver on DWI in the present study, however, were not higher than that between metastatic liver cancer and surrounding hepatic tissue. This finding might have been because the signal intensity of HCC was not so high as metastatic tumors and the signal intensity of the cirrhotic liver was irregularly increased in our study (data not shown), probably because of marked liver fibrosis, as previously noted\textsuperscript{[19-21]}. High signal intensities were found in most malignant focal hepatic lesions and DWI was useful for identifying them, as it was in previous studies\textsuperscript{[17,18]}.

However, the findings of benign lesions differed from malignant lesions. Cysts and hemangiomas are most frequently found in the benign lesions of the liver. In the present study, the cysts had low or no signal intensities and hemangiomas had high or low signal intensities, similar to previous studies\textsuperscript{[22]}. Such lesions are usually diagnosed using major imaging modalities, such as ultrasonography and enhanced CT. However, because these lesions are small and multiple, differential diagnosis against malignant focal hepatic lesions is often difficult, even using these modalities. The characteristics of cysts on DWI, however, in which the cysts express low or no signal intensities, can enable differential diagnosis against malignant focal hepatic lesions, as shown in Figure 4.

Administration of SPIO in the present study reduced the signal intensity of liver parenchyma on DWI and increased the RCR of malignant focal hepatic lesions, but did not often increase the RCR of hepatic hemangiomas. Therefore, SPIO was quite useful for differential diagnosis, especially between small metastatic liver cancers and hepatic hemangiomas.

We used a high $b$ value (1000 s/mm$^2$) for DWI because a high $b$ value allows delineation of malignant tumors with excellent conspicuity owing to the generally suppressed background noise. Furthermore, the differences in the RCR between malignant and benign lesions were increased with a high $b$ value. However, this characteristic of DWI occasionally hinders defining the anatomical location of the abnormal signal on DWI. Therefore, the location of the signal must be correlated with ordinary T2 images by making the slice thickness, interslice gap, and fields of view uniform among these images. Recent developments in fusion software can readily resolve this problem by anatomically overlapping DWI onto ordinary T2 images. Such fused images might allow improved detection of malignant tumors\textsuperscript{[23]}.

ADC is a quantitative parameter calculated from DWI. ADC combines the effects of capillary perfusion and water diffusion in the extracellular and extravascular space\textsuperscript{[24]}. ADC is helpful for characterizing focal and diffuse diseases in the body. Several studies have reported that ADC can contribute to the differential diagnosis of benign and malignant focal lesions in the liver\textsuperscript{[16,25]}. Our results also revealed the contribution of ADC to the characterization of focal hepatic lesions. The ADC of malignant lesions was significantly lower than that of the surrounding hepatic tissue, whereas the ADC of benign lesions was higher than that of the surrounding hepatic tissue. Benign lesions, hemangiomas, and cysts in particular had high ADCs, even if they had high signal intensities on conventional DWI. The signal intensity of DWI includes both restricted diffusion and the effect of tissues with high T2 relaxation times, which is called the “T2 shine-through” effect. This might be why hemangiomas and cysts sometimes have high signal intensities on DWI. In any case, those results will be useful for differential diagnosis of malignant and benign focal hepatic lesions. For large lesions, however, the ADC was often markedly inhomogeneous on the locations and slices in the lesion. ADCs also seem to differ according to the machine used, the set-up conditions of the machine, and each human body\textsuperscript{[26]}. Thus, ADC must be carefully used in the evaluation of lesion characteristics.

A few malignant lesions could not be visualized by DWI in our study. These lesions were mainly located on the left lobe, just under the diaphragm. DWI is known to be extremely sensitive to motion. During clinical image interpretation of MRI, a signal drop is often encountered in the lateral segment of the liver, which is assumed to be due to cardiac pulsation. Not only the signal intensity of DWI, but also ADC, is thought to be incorrect for the lateral segment just under the diaphragm\textsuperscript{[12,23,25]}. Further studies need to be conducted to better understand the characteristics of DWI.

This study had some limitations. First, the subjects were a heterogeneous group, and the number of cases was relatively small. Second, histological proofs were not completely obtained, especially for the benign lesions. Therefore, the sensitivities and specificities of DWI cannot be reported here. Third, placement of the region of interest cursor might not be objective enough for measuring ADC and RCR. Additionally, inhomogeneity of hepatic lesions and motion may have affected the accuracy of the calculations, because the DWI was acquired with free breathing\textsuperscript{[23]}. Despite these limitations, we believe that DWI is a very useful imaging modality for identifying malignant focal lesions in the liver. Recently, a new MRI contrast medium, gadolinium-ethoxybenzyl-diethyleneetriamine pentaacetic acid (Gd-EOB-DTPA), has been used for diagnosis of HCC. We plan to combine both Gd-EOB-
DTPI and DWI for diagnosing focal hepatic lesions.

In conclusion, DWI is a simple and sensitive method for screening focal hepatic lesions. SPIO administration can effectively improve the RCR of metastatic liver cancers. ADC measurement is occasionally helpful for differential diagnosis of malignant and benign small focal hepatic lesions.

REFERENCES

1 Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505

2 Sorensen AG, Buonanno FS, Gonzalez RG, Schwamm LH, Lev MH, Huang-Hellinger FR, Reese TG, Weisskoff RM, Davis TL, Suwanwela N, Can U, Moreira JA, Porat L, Koroshetz WJ, Warach S. Image contrast in human brain: hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echoplanar MR imaging. Radiology 1994; 199: 391-401

3 Moseley ME, Kucharzczk J, Minniti-Swivitch J, Cohen Y, Kurbanwicz J, Derugin N, Asgari H, Norman D. Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am J Neuroradiol 1990; 11: 423-429

4 Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T. Diffusion-weighted MR imaging with single-shot echoplanar imaging in the upper abdomen: preliminary clinical experience in 61 patients. Abdom Imaging 1999; 24: 456-461

5 Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004; 22: 275-282

6 Vogl TJ, Schwarz W, Blume S, Pietisch M, Shamsi K, Franz M, Lobeck H, Balzer T, del Tredici K, Neuhaus P, Felix R, Hammerstingl RM. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biparametric CTAP and intraoperative US. Eur Radiol 2003; 13: 262-272

7 Naganawa S, Sato C, Nakamura T, Kumada H, Ishigaki T, Miura S, Maruyama K, Takizawa O. Diffusion-weighted images of the liver: comparison of tumor detection before and after contrast enhancement with superparamagnetic iron oxide. J Magn Reson Imaging 2005; 21: 836-840

8 Kwiat D, Einav S, Navon G. A decoupled coil detector array for fast image acquisition in magnetic resonance imaging. Med Phys 1991; 18: 251-265

9 Nasu K, Kuroki Y, Sekiguchi R, Kazama T, Nakajima H. Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis? J Comput Assist Tomogr 1999; 231: 456-461

10 Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura H. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR Am J Roentgenol 1999; 173: 393-398

11 Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231: 305-332

12 Kim YK, Kwak HS, Han YM, Kim CS. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arteriography using 16-slice multidetector computed tomography. J Comput Assist Tomogr 2007; 31: 702-711

13 Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, Yamamoto S, Mutoori K, Ueda T. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR Imaging. Radiology 2006; 239: 122-130

14 Parikh T, Drew SJ, Lee VS, Wong S, Hecht EM, Babb JS,
Taouli B. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. *Radiology* 2008; 246: 812-822

19 **Lewin M**, Poujol-Robert A, Boelle PY, Wendum D, Lasnier E, Viallon M, Guechot J, Hoeffel C, Arrive L, Tubiana JM, Poupon R. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. *Hepatology* 2007; 46: 658-665

20 **Girometti R**, Furlan A, Bazzocchi M, Soldano F, Isola M, Toniutto P, Bitetto D, Zuiani C. Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients. *Radiol Med* 2007; 112: 394-406

21 **Taouli B**, Tolia AJ, Losada M, Babb JS, Chan ES, Bannan MA, Tobias H. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. *AJR Am J Roentgenol* 2007; 189: 799-806

22 **Koyama T**, Tamai K, Togashi K. Current status of body MR imaging: fast MR imaging and diffusion-weighted imaging. *Int J Clin Oncol* 2006; 11: 278-285

23 **Bruegel M**, Holzapfel K, Gaa J, Woertler K, Waldt S, Kiefer B, Stemmer A, Ganter C, Rummeny EJ. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. *Eur Radiol* 2008; 18: 477-485

24 **Kuroki Y**, Nasu K, Nawano S, Sekiguchi R. Diffusion-weighted MR imaging of the liver. *Nichidoku-iho* 2007; 52: 72-81

25 **Nasu K**, Kuroki Y, Sekiguchi R, Nawano S. The effect of simultaneous use of respiratory triggering in diffusion-weighted imaging of the liver. *Magn Reson Med Sci* 2006; 5: 129-136